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Background: Attitudes of Australian CF healthcare professionals toward population-based cystic ﬁbrosis (CF) carrier screening were examined.
Method: A purpose-designed questionnaire was distributed to 111 respiratory physicians and 30 CF clinic coordinators throughout Australia.
Results: Seventy-one questionnaires (52 physicians and 19 coordinators (46.8%, 63.3% respectively)) were returned.
Forty respondents (56.3%) supported population-based carrier screening for CF. Support for screening was associated with rating the factors:
carrier risk being 1 in 25 (OR 1.72 (1.12, 2.65)), reassurance when both partners test negative (OR 1.67 (1.12, 2.46)) and the daily treatment
regimen for CF patients (OR 1.59 (1.05, 2.42)) as important. Opposition to screening was associated with identifying potential discrimination
against carriers as a disadvantage (OR 0.3 (0.12, 0.88)), and limitations of predicting clinical outcomes as a barrier (OR 0.46 (0.25, 0.83)).
Conclusions: There is moderate support for population-based carrier screening for CF by Australian CF healthcare professionals. Perceived
barriers to implementation are surmountable.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Carrier screening; Cystic ﬁbrosis carrier screening; Genetic screening; Population screening; Attitudes1. Introduction
Cystic fibrosis (CF) is the most common, severe autosomal
recessive condition affecting Australian children. It causes
progressive suppurative lung disease and pancreatic exocrine
insufficiency, which results in reduced life expectancy [1].
Although median life expectancy has increased to the mid-30s,
there is no cure and daily treatments are rigorous [2]. CF is
caused by mutations in the cystic fibrosis transmembrane
conductance regulation (CFTR) gene and testing for the most
common mutations is possible, facilitating diagnosis and⁎ Corresponding author at: Department of RespiratoryMedicine, Royal Children's
Hospital, Parkville Victoria 3052, Australia. Tel.: +61 3 9345 5844; fax: +61 3 9349
1289.
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http://dx.doi.org/10.1016/j.jcf.2013.06.009lishedcarrier screening. In Australia most babies with CF are
detected by newborn screening and two thirds of parents with
an affected child elect to use pre-natal testing on subsequent
pregnancies [3]. The carrier frequency in Caucasian popula-
tions is 1 in 25 and over 90% of parents of children born with
CF were unaware of their carrier status [4]. Many of these
parents have indicated a preference for knowledge of their CF
carrier status prior to the birth of their child with CF [4–6]. A
population-based carrier screening program for CF could
facilitate this.
Population-based carrier screening for CF has been
discussed since 1991 when CFTR mutation detection became
relatively easy to do. A successful program ran in Edinburgh
for many years and small programs have been developed in
other European centers [7–11]. Only the United States offers a
population-based program (although fee-for-service) followingby Elsevier B.V. All rights reserved.
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and Medical Geneticists [12]. In Australia, two small programs
have been running on a fee for service basis but the majority of
couples planning a pregnancy, or in the early stages, are not
made aware of the programs despite a statement from the
Human Genetics Society of Australasia in support of popula-
tion screening for CF [13].
Given that CF satisfies the criteria of the World Health
Organisation's criteria for an acceptable screening program and
concurs with a decision support guide developed to assist policy
makers in this area [14], it is unclear why population-based
carrier-screening for CF in Australia and other countries has been
slow to evolve. Part of the answer may be fragmented health care
and ambivalence by key stake-holders. This is despite routine
screening for chromosomal abnormalities during pregnancy,
detection of carriers for hemoglobinopathies and carrier screen-
ing for a range of genetic conditions in Ashkenazi Jews [15,16].
There is no literature that specifically assesses the attitudes of CF
healthcare workers toward population-based carrier screening.
Medical professionals involved with the care of people with CF
are well placed to understand the severity of CF and its impact on
quality of life for patients and their families.
The aim of this study was to investigate the attitudes of
healthcare professionals caring for patients with CF toward
population-based carrier screening for cystic fibrosis.
2. Materials and methods
This was a cross-sectional questionnaire study.
2.1. Participants
Physicians were identified through the CF special interest
group of the Thoracic Society of Australia and New Zealand
(TSANZ). The clinic coordinators were identified through the CF
Nurses Network. A questionnaire and participant information
statement was sent to all CF respiratory physicians (n = 120) by
the TSANZ and directly to CF clinic coordinators (n = 30) in
Australia. Consent was implicit in completion of the question-
naire and results were anonymised. One reminder was sent
by mail.
2.2. Questionnaire
The questionnaire was purposely designed for this study. Six
allied health workers and three senior medical fellows involved
with the care of CF patients piloted the questionnaire.
The questionnaire had four domains: demographics, attitudes
about CF, knowledge of carrier screening for CF, and attitudes
toward population-based carrier screening for CF. Five- and
6-point Likert scales were used to assess respondents' views of the
severity of CF, how manageable they considered raising a child
with CF and significance of various concerns to CF patients
and their families. Four statements relating to CF carrier screening
knowledge were included. Respondents could indicate the
statement was true, false or unsure. Support for population-based
carrier screening for CF was assessed via a binary outcome. Theimportance of 13 factors and 6 potential barriers to a respondent's
decision to support or not support screening were assessed via a
6-point Likert scale. The primary benefits and possible disadvan-
tages of CF screening along with when and who to offer screening
to were assessed via binary outcome measures. Respondents were
asked to nominate one of five statements regarding the role they
believe their profession should play in the development of a
population-based carrier-screening program for CF. The question-
naire contained space for qualitative responses to specific
questions.
2.3. Statistical analysis
Analyses were undertaken using STATA release 11 for Mac.
Descriptive statistics were used for data obtained from the
questionnaire, including demographics. The significance of
concerns about the impact of CF on the lives of patients and their
families, and the importance of factors regarding CF in their
decision to support screening, and potential barriers to screening,
originally assessed via 6-point Likert scales, were regrouped into
unimportant (1 and 2), neutral (3 and 4) and important (5 and 6)
categories for summary statistics. Responses to questions investi-
gating knowledge of CF carrier screening were reclassified as
correct or not correct (including unsure responses). Proportions of
correct responses, and corresponding 95% confidence intervals,
were compiled. Chi-square analysis was used to assess the
differences in categorical demographic variables between the two
professions. The continuous numerical demographic characteris-
tics of physicians and clinic coordinators were compared by t-test
analysis, following ascertainment of normality of data.
Predictors of the binary outcome variable ‘support of
population-based carrier screening for CF’ (yes or no) were
examined by univariable logistic regression analysis. Results
are expressed as odds ratios (OR) with 95% confidence
intervals (CI) and p-values. p-Values of b0.05 were consid-
ered statistically significant. Questions originally assessed via
Likert scales, were not regrouped into important, neutral and
unimportant categories for regression analysis.
Multivariable regression analysis of all variables that had a
significant association with support for screening in univariate
analysis was also conducted.
2.4. Ethics
Ethics approval for the study was granted by University of
Melbourne, Health Science Human ethics Sub-Committee on.
(Ethics ID 0931151).
3. Results
3.1. Response rate and demographic variables
Of 120 questionnaires distributed to respiratory physicians,
nine were excluded (seven addressee unknown, one physician
did not treat patients with CF and one non-medical researcher).
Of the remaining 111 questionnaires, 52 were returned (response
rate 46.8%). Nineteen of 30 CF clinic coordinators completed the
Table 2
Number and % of correct responses to questions on CF carrier screening.
Question No. respondents
correct (n = 71)
% 95%
CI
1. CF carrier screening can identify all CF
carriers (correct = false)
68 95.8% 91,100
2. If both members of a couple are tested
and only one partner is identified as a
carrier, there is still a small chance this
couple may have a child with CF
(correct = true)
66 93.0% 87,99
3. A negative test results indicates a person
cannot be a carrier of CF (12-mutation
panel) (correct = false)
67 94.4% 89,100
4. Newborn screening identifies most
carriers of CF (correct = false)
31 43.7% 32,55
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was 50.4% (71/141).
The demographic variables of respondents are presented in
Table 1. A larger proportion of clinic coordinators were females
(p b 0.001) while respiratory physicians were marginally older.
(47.1 (SD 1.3) years vs. 41.8 (SD 1.7) years) (p = 0.032).
No other significant differences were found between demo-
graphic variables of physicians and clinic coordinators.
3.2. Knowledge of CF carrier screening
The majority of the knowledge questions were answered
correctly by respondents. (Table 2) However, only 43.7% of
respondents correctly identified that newborn screening does not
identify most carriers of a CF mutation. Professionals working in
pediatric clinics were over nine times more likely than those
working in adult clinics to answer this question correctly. (OR
9.16, 95%CI 2.49, 33.69).
3.3. Support for population-based CF carrier screening
Forty of the 71 respondents (56.3%) were in favor of
population-based carrier screening for CF, 26 (36.6%) were not
in favor and 5 (7.0%) were unsure.
3.4. Attitudes toward cystic fibrosis
Cystic fibrosis is considered a severe to moderately severe
disease by the majority of respondents (94.3%). All respon-
dents perceived raising a child with CF as more difficult than
raising a healthy child. Sixty respondents (84.5%) rated raising
a child with CF as difficult or very difficult, 46 (64.7%) ratedTable 1
Demographic characteristics of respondents.
Variable Responses (n) %
Profession 70 a
Physician 51 72.9%
Male (35) (68.6%)
Female (16) (31.4%)
Clinic coordinator 19 27.1%
Male (1) (5.3%)
Female (18) (94.7%)
Type of clinic 68 b
Adults only 22 32.4%
Paediatric only 43 63.2%
Adult + pediatric 3 4.4%
Religious affinity 71
Yes 35 49.3%
No 36 50.7%
Influence of religion on professional decisions 41 c
Not at all — neutral 37 90.2%
Very much 4 9.8%
Completely 0 0%
a One physician did not provide any demographic data.
b Two respondents did not provide these data.
c Most respondents who said no to religious affinity did not complete this
question.this difficult but most parents cope, and 14 (19.7%) rated this as
very difficult, many parents do not cope.
The most significant concerns about CF to patients and
families according to CF clinicians were ‘daily treatments,’ with
63 of the 71 respondents (88.7%) rating this of high significance,
and ‘shortened life span,’ identified as highly significant by 61
respondents (85.9%).
3.5. Factors influencing decision regarding CF carrier
screening
The importance of 11 different factors in their decision to
support or not support screening, as rated by respondents is
shown in Fig. 1. The factors rated as important by more than
50% of the respondents were: ‘clinical picture and prognosis of
CF’ (48 of 71 respondents, 67.6%), the ‘quality of life of people
with CF’ (42 of 71 respondents, 59.2%), the ‘carrier risk beingFig. 1. Perceived importance of factors by respondents in deciding whether or
not to support population-based carrier screening.
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regimen’ (37 of 71 respondents, 52.1%). The factors considered
least important by respondents were ‘fear of litigation’ (2 of 70
respondents, 2.8%), and ‘beliefs about termination of pregnan-
cy’, (4 of 71 respondents, 5.6%).Table 3
Univariable analysis of the association between support for population-based
carrier screening for CF and
a) perceived importance of factors about CF.
b) potential barriers to screening.
c) perceived primary benefits of screening.
d) perceived disadvantages of screening.
Variable Univariable analysis3.6. Potential barriers to CF carrier screening
Fig. 2 shows respondents' rating of five possible barriers to
CF carrier screening. The ‘inability to accurately predict clinical
outcomes associated with some CF alleles’ was considered the
most significant barrier with 67.1% of respondents rating this as
important. ‘Insufficient time and resources’ was also considered
a significant barrier by 41 of 70 respondents (58.6%). Carrier
screening for CF ‘not being cost effective’ was the least noted
barrier, with only 21 of 67 respondents (31.3%) rating this
important. 50.7% of respondents considered people having to
pay as an important barrier.OR 95% CI p
a) Factors important in decision to screen
CF child risk 1/2500 1.15 0.79, 1.68 0.453
Carrier risk 1/25 1.72 1.12, 2.65 0.014 ⁎
Reassurance if both negative 1.59 1.05, 2.42 0.030 ⁎
b100% sensitivity 0.76 0.53, 1.09 0.132
Clinical prognosis 1.40 0.93, 2.11 0.111
Possible improved treatment 1.02 0.72, 1.45 0.922
Fear of litigation 1.42 0.84, 2.39 0.195
Beliefs regarding termination of pregnancy 1.19 0.80, 1.75 0.387
Quality of life 1.28 0.85, 1.91 0.233
Possible cure 1.21 0.86, 1.69 0.271
Daily treatment regimen 1.67 1.12, 2.46 0.011 ⁎
b) Importance of potential barriers
Lack of time/resources (n = 65) 1.07 0.77, 1.50 0.681
Inability to predict clinical outcomes (n = 65) 0.46 0.25, 0.83 0.011 ⁎3.7. Primary benefits and potential disadvantages of CF
carrier screening
The ‘identification of individuals and couples at risk of having
a child with CF’ was the most frequently indicated benefit by 52
respondents (73.2%), followed by ‘to reduce the number of
children born with CF’ by 42 (59.2%) and to ‘increase awareness
of CF in the community’ by 31 (43.7%) respondents respectively.
‘Potential anxiety of identified carriers’ was the most
commonly identified disadvantage of screening, indicated by 62
respondents (87.3%). Forty respondents (56.3%) nominated
potential ‘discrimination and stigmatization of carriers’ as a
possible disadvantage.Fig. 2. Clinician rating of importances of potential barriers to population-based
carrier screening for CF in Australia.3.8. Factors correlating with attitude to support screening
Factors associated with the decision to support screening are
presented in Table 3.
Individuals who rated a carrier risk of 1 in 25 as an important
factor in their decision were 1.72 times more likely to support
screening compared to those who did not consider this
important (OR 1.72 (95% CI 1.12, 2.65)). Considering the
daily treatment regimen and reassurance when both partners
test negative as important were also associated with a 1.67 andLack of community knowledge (n = 64) 0.75 0.51, 1.10 0.144
Not cost effective (n = 62) 0.73 0.51, 1.03 0.076
If people have to pay (n = 64) 1.46 1.02, 2.09 0.041 ⁎
c) Perceived primary benefits
Reduce number children with CF
Yes 1.29 0.47, 3.49 0.621
No ref –
Identification of couples at risk
Yes 6.00 1.78, 20.19 0.004 ⁎
No ref –
Increase awareness of CF
Yes 4.51 1.49, 13.64 0.008 ⁎
No ref –
d) Perceived potential disadvantages
Anxiety of carriers
Yes 0.91 0.20, 4.20 0.907
No ref
Discrimination and stigmatization of carriers
Yes 0.30 0.10, 0.88 0.028 ⁎
No ref –
Step toward designer children
Yes 0.68 0.21, 2.17 0.513
No ref –
Other health issues higher priority
Yes 0.40 0.12, 1.32 0.132
No ref –
⁎ Statistically significant p b 0.05.
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for screening (OR 1.67, (95% CI 1.12, 2.46) and OR 1.59 (95%
CI 1.05, 2.42) Respondents who indicated identification of
individuals or couples at risk of having a child with CF as a
primary benefit were 6 times more likely to support screening
(OR 6.0 (95% CI 1.78, 20.19). Identification of increasing
awareness of CF as a benefit was associated with a 4.5 fold
increase in support for screening.(OR 4.51 (95% CI 1.49, 13.64)
Support for screening was also associated with identification of
‘people having to pay for screening’ as a potential barrier (OR
1.46 (95% CI 1.02, 2.09).
Only two factors were associated with not being in support
of screening. Respondents noting discrimination of carriers as a
possible disadvantage were more than three times less likely to
support screening. (OR 0.3 (95% CI 0.12, 0.88) and those
identifying the inability to predict clinical outcomes as a
potential barrier were approximately two times less likely to
support screening (OR 0.46 (95% CI 0.25, 0.83.)
Univariable logistic regression analysis revealed no statisti-
cally significant association between any of the demographic
variables listed in Table 1 and support for screening. A larger
proportion of clinic coordinators were in favor of screening
when compared with physicians (72% vs. 55%), however this
difference was not statistically significant. Similarly, gender,
type of clinic, age of respondent, years of experience with CF
patients, state of practice and religious affinity were also found
not to have an association with support for screening.
After adjusting for other factors found to associate with
attitude toward screening, none of the variables associated with
support for population-based CF carrier screening were found
to be significant using multivariate regression analysis.3.9. Informing people of the availability of CF carrier
screening
Fifty-one out of 67 respondents (72.9%) had not informed
people with no family history of CF that carrier screening was
available, despite 70.6% of these respondents being aware that
it was. Respondents who had informed people with no family
history of CF of the availability of carrier screening for CF were
almost 4 times more likely than those who had not informed
people to have a positive attitude toward population-based
carrier screening for CF (OR 3.95 (95% CI 1.00, 15.54)).3.10. Perceived role in development of a CF carrier screening
program in Australia
Fifty of 67 respondents (74.7%) believe that they have a role
in development of a population-base carrier-screening program
for CF in Australia. Thirty-four respondents (50.8%) believed
they have a role as an advocate for their patients, and 16
(23.9%) believed they have a role as they have firsthand
knowledge of the impact of CF on patients and families. Only 4
respondents (6.0%) reported a conflict of interest between
caring for patients and advocating for a program that may
prevent the births of individuals with CF.4. Discussion
This is the first study to examine the attitudes and beliefs of
CF respiratory physicians and clinic coordinators toward
population-based carrier screening for CF, and indicates that a
small majority (56.3%) of respondents were in favor of
screening. Nearly all respondents considered CF to be a severe
disease for both patient and their family. Given that this view
was so common among respondents, the divergence in attitudes
toward CF carrier screening must be due to other beliefs. This
study attempted to assess what other beliefs respondents held
and how these correlate with their support for screening.
The factors that were most influential for respondents in
making their decisions about population-based CF carrier
screening were the clinical picture and prognosis of CF: the 1
in 25 population risk of being a carrier, the severity of CF, the
quality of life for patients and the daily treatment regimen.
However, of the factors investigated, only the population
carrier risk and treatment regimen were significant factors
correlating with support for population based carrier screening
for CF. A less significant factor was reassurance to couples
when both partners test negative.
In considering any screening program there is an imperative to
identify barriers that might lead to benefits being outweighed by
risks or harms. The main barriers to population-based carrier
screening identified by this studywere the ‘limitations of predicting
clinical outcomes,’ and ‘insufficient time and resources for
providers.’ Only the identification of the difficulty of providing
accurate prognoses as a significant barrier correlated with a
decision not to support screening. While genotype-phenotype
correlations in CF are limited [17], the HGSA recommendations
suggest only selecting mutations in a screening panel known to be
associated with severe (pancreatic insufficient) disease. This is the
approach taken by most overseas programs [7,12,18–20].
‘Insufficient time and resources for screening providers to
inform and counsel patients’ is a consistent theme in many
studies involving health professionals’ attitudes toward
population-based carrier screening for CF [6,21,22]. Although
rating insufficient resources did not correlate with either
support or lack of support, this result still suggests that some
respondents fear that a program not appropriately resourced
may do more harm than good. In the population-based
carrier-screening program in Victoria, Australia, which is
offered through participating obstetrics and antenatal services,
pre-test information was by way of brochure and website.
Most carriers were informed of their results by telephone, and
all their partners were tested. Only carrier couples required
face-to-face counseling [19].
Over 50% of respondents considered that payment for carrier
testing was a significant barrier to its uptake. Presumably this
makes the test available only to those that can afford it, or only
offered to patients whom the healthcare provider believes is
willing to pay for it. Government funding for the test would
overcome this barrier to a large extent.
The potential disadvantages of screening identified by
respondents in this study were potential anxiety and also
discrimination and stigmatization of identified carriers. Only
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screening. A number of studies have demonstrated that while
anxiety is high among people identified as carriers, this is usually
rapidly relieved by their partners testing negative [23–26]. In the
program in Victoria, Australia, offered through antenatal care
providers, none of the carriers with a test negative partner
requested face to face counseling (despite the offer) and did not
register higher anxiety scores than non-carriers when questioned
a year or more later [19,27]. The possibility of discrimination and
stigmatization of identified carriers has been raised as a concern
by other health professionals in studies investigating CF carrier
screening, although there is no published information to suggest
that social stigmatization of carriers is a problem, and most
jurisdictions have ruled against health insurance providers using
carrier status to the disadvantage of the carrier [6]. A number of
studies also support that increased anxiety or discrimination is not
considered overly significant by the community itself [26,27].
Another strong finding of this study is the belief by CF
healthcare professionals that they have a key role in the
development of a carrier-screening program for CF, regardless
of their attitude toward screening. This was based on their first
hand knowledge of the impact of CF on patients and families and
does not indicate a conflict of interest in developing a carrier
screening program.
It is surprising that many respondents believed that most CF
carriers are detected by newborn screening (NBS), although
these were mostly adult physicians who may not be familiar
with NBS. The apparently poor understanding of NBS could be
due to the assumption that all babies are genetically screened
for CF via NBS, not just those with elevated immunoreactive
trypsinogen (IRT), or the misunderstanding that all babies who
are carriers of a CFTR mutation will have elevated IRT levels.
Carrier detection (false positives) is an unwanted side effect of
NBS and while nearly twice the expected number of carriers are
detected, the majority are not [28].
It is worth noting that most of the CF healthcare professionals
have not informed patients and families with no family history of
CF of the availability of carrier testing, regardless of their attitude
toward screening or their perceived role in development of a
screening program. Whether this is due to their not seeing
patients needing this referral or due to a difference between stated
beliefs and actual behavior is complex and merits further
investigation.
Our study has some limitations. The response rate of the CF
physicians was disappointing, but may be reflected in the list of
the CF special interest group of the TSANZ that allows anyone
who expresses an interest in CF to join. The number of
physicians actually providing care is likely to be much smaller.
The possibility of recruitment bias exists in that those with the
strongest feelings (either way) were most likely to participate.
Further research is needed in Australia to assess if
population-based CF carrier screening aligns with the expecta-
tions of other medical practitioners Two recent Australian studies
indicate acceptance for population based carrier screening for CF
among the general community and CF patients and families,
although these studies were limited in scope and further research
is warranted to confirm their findings [26,29]. In a more recentstudy 83% of participating Australian obstetricians expressed
support for carrier screening for CF, identifying cost, time
constraints and availability of supporting services as the main
practical barriers [30].
5. Conclusion
Our study suggests moderate support for population-based
carrier screening for CF in Australia by CF physicians and clinic
coordinators. We consider that many of the perceived barriers to
implementation of a large-scale program are surmountable.
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